Home » Topics » BioWorld Science

BioWorld Science
RSS

First patient dosed in phase II study of AG-10 in ATTR cardiomyopathy

May 4, 2018

Altum Pharmaceuticals acquires Lexi Pharma

May 4, 2018

FDA approves AndexXa to reverse factor Xa inhibitors

May 4, 2018

New albumin-binding compounds from CytRx show antitumor activity in xenograft models

May 4, 2018

Moderna Therapeutics and Merck & Co. expand cancer collaboration

May 4, 2018

FDA joint advisory committee meeting recommends against stannsoporfin

May 4, 2018

Phase I trial begins of CS-1002 for advanced solid tumors begins in Australia

May 4, 2018

Dong-A Socio Holdings identifies Mer inhibitors

May 4, 2018

RTI International discovers new APLNR agonists

May 4, 2018

Phase III trial of ranibizumab biosimilar FYB-201 meets primary endpoint

May 4, 2018

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...